Price School of Public Policy, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA.
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Pharmacoeconomics. 2022 Jul;40(7):647-652. doi: 10.1007/s40273-022-01150-w. Epub 2022 May 13.
Commercial payers that ultimately decide to cover aducanumab or other Alzheimer's disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer's disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer's disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer's disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer's disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.
商业支付方最终决定是否覆盖 aducanumab 或其他阿尔茨海默病治疗药物，可能需要创新的支付工具，以最小化这些治疗方法的不确定收益和高昂成本所带来的财务风险。基于已发表的证据，我们提出了两种适用于阿尔茨海默病疾病修饰疗法的不同类型的支付模型，并提出了克服实施挑战的四项策略。这些策略包括制定阿尔茨海默病结局测量的最佳实践、投资收集真实世界数据的基础设施、提高阿尔茨海默病登记数据的代表性，以及整合诊断、治疗和支付领域。这些重要步骤可以使阿尔茨海默病新兴疗法的可及性在长期内更加可持续，并为未来在其他适应证中获得新型疗法提供蓝图。
